Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 9/20 | 0.70 |
| ▸ | CTSK | P43235 | 7/20 | 0.70 |
| ▸ | CTSS | P25774 | 5/20 | 0.70 |
| ▸ | CTSH | P09668 | 4/20 | 0.70 |
| ▸ | CTSL | P07711 | 4/20 | 0.70 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.70 |
| ▸ | CTSV | O60911 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19983276 | 1.00 | CTSB (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982958 | 1.00 | CTSB (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL23023384 | 0.99 | CTSB (0.69) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL17646280 | 0.92 | CTSB (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19983202 | 0.92 | CTSK (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL28341603 | 0.92 | CTSB (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19983273 | 0.92 | CTSK (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19983035 | 0.88 | CTSB (0.71) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL23023357 | 0.87 | CTSB (0.70) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19983051 | 0.86 | CTSB (0.71) | CTSBCTSKCTSSCTSHCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.